Design Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.61
- Today's High:
- $2.77
- Open Price:
- $2.67
- 52W Low:
- $4.9
- 52W High:
- $26.3
- Prev. Close:
- $2.67
- Volume:
- 569673
Company Statistics
- Market Cap.:
- $308.26 million
- Book Value:
- 5.594
- Revenue TTM:
- $33000
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-48613000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -13.48%
- Return on Equity TTM:
- -20.3%
Company Profile
Design Therapeutics Inc had its IPO on 2021-03-26 under the ticker symbol DSGN.
The company operates in the Healthcare sector and Biotechnology industry. Design Therapeutics Inc has a staff strength of 64 employees.
Stock update
Shares of Design Therapeutics Inc opened at $2.67 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.61 - $2.77, and closed at $2.7.
This is a +1.12% increase from the previous day's closing price.
A total volume of 569,673 shares were traded at the close of the day’s session.
In the last one week, shares of Design Therapeutics Inc have increased by +8.87%.
Design Therapeutics Inc's Key Ratios
Design Therapeutics Inc has a market cap of $308.26 million, indicating a price to book ratio of 1.289 and a price to sales ratio of 22642.0122.
In the last 12-months Design Therapeutics Inc’s revenue was $33000 with a gross profit of $-48613000 and an EBITDA of $-75421000. The EBITDA ratio measures Design Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Design Therapeutics Inc’s operating margin was 0% while its return on assets stood at -13.48% with a return of equity of -20.3%.
In Q1, Design Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Design Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.28 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Design Therapeutics Inc’s profitability.
Design Therapeutics Inc stock is trading at a EV to sales ratio of 11004.3527 and a EV to EBITDA ratio of -1.68. Its price to sales ratio in the trailing 12-months stood at 22642.0122.
Design Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $324.74 million
- Total Liabilities
- $9.05 million
- Operating Cash Flow
- $19.73 million
- Capital Expenditure
- $87000
- Dividend Payout Ratio
- 0%
Design Therapeutics Inc ended 2024 with $324.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $324.74 million while shareholder equity stood at $312.82 million.
Design Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $9.05 million in other current liabilities, 6000.00 in common stock, $-130058000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $28.81 million and cash and short-term investments were $315.39 million. The company’s total short-term debt was $658,000 while long-term debt stood at $0.
Design Therapeutics Inc’s total current assets stands at $318.94 million while long-term investments were $0 and short-term investments were $286.58 million. Its net receivables were $974000.00 compared to accounts payable of $2.74 million and inventory worth $0.
In 2024, Design Therapeutics Inc's operating cash flow was $19.73 million while its capital expenditure stood at $87000.
Comparatively, Design Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.7
- 52-Week High
- $26.3
- 52-Week Low
- $4.9
- Analyst Target Price
- $22.4
Design Therapeutics Inc stock is currently trading at $2.7 per share. It touched a 52-week high of $26.3 and a 52-week low of $26.3. Analysts tracking the stock have a 12-month average target price of $22.4.
Its 50-day moving average was $5.23 and 200-day moving average was $6.94 The short ratio stood at 24.04 indicating a short percent outstanding of 0%.
Around 3697.2% of the company’s stock are held by insiders while 7368.4% are held by institutions.
Frequently Asked Questions About Design Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company’s portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.